Determining Current Insulin Pen Use Practices and Errors in the Inpatient Setting.
The use of insulin pens in the inpatient setting has continued to be a controversial decision. Insulin pens provide several advantages, but given significant reports of medication errors, several organizations have issued alerts to caution users about safety concerns. A survey was conducted to assess the prevalence of insulin pen use and current utilization trends in the inpatient setting.



The 31-question guided-logic survey was developed based on review of primary literature regarding insulin pen utilization and evaluated by a panel of medication safety experts from a variety of health care settings. The survey was sent electronically to subscribers of medication safety organizations.



The survey was completed by 474 respondents. Approximately three fourths of respondents indicated insulin pens were on formulary at their institution (n = 332; 74%). Of those who have had insulin pens on formulary, 15% (n = 49) are no longer using them. The most common reasons for not utilizing pens were cost and safety concerns. Pens were reported to be stored in the pharmacy prior to administration (n = 230; 78%) and in a patient's bin (n = 202; 69%) afterward. More than half of respondents use two patient identifiers on the pen and label with a bar code. Approximately 30% reported that an insulin pen has been used on more than one patient at least once in their institution, while 6% were not sure.



Insulin pens are widely being used in the inpatient setting. Various mitigation strategies are employed to reduce the risk of harm associated with insulin pen use. Health care professionals believe insulin pens are clinically useful and can be used safely in the inpatient setting. Many organizations and expert panels disseminate best practices in an effort to help ensure their safety. Further studies are needed to assess and validate the risk mitigation strategies identified through this research.
Formerly Regulatory Pharmaceutical Fellow in Medication Safety, Purdue University, Indianapolis; Therapeutic Consultant for Diabetes in US Health Outcomes, Eli Lilly and Company, Indianapolis. Electronic address: katelyn.e.jensen@gmail.com.
Katelyn E
KE
Brown
Associate Director, Center for Medication Safety Advancement; Courtesy Clinical Assistant Professor of Pharmacy Practice, Purdue University, Indianapolis; Member, Editorial Advisory Board, The Joint Commission Journal on Quality and Patient Safety.
John B
JB
Hertig
D004304:Dosage Forms; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007277:Injections, Jet; D007297:Inpatients; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D008508:Medication Errors / Q000517:prevention & control*; D009339:Needles; D061214:Patient Safety; D011795:Surveys and Questionnaires; D014600:Utilization Review
D004304:Dosage Forms; D007004:Hypoglycemic Agents; D007328:Insulin